<pad> In the ATP analysis, efficacy against HPV 16 or HPV 18 persistent infection was 90.9% (95% CI = 82.0–95.9) and in the ITT analysis was 49.0% (95% CI = 38.1–58.1).Among women who were HPV 16 or 18 DNA positive at enrollment into the clinical trials, either seropositive or seronegative, the vaccine had no efficacy against progression of infection to disease ( 159) or impact on clearance of infection of that HPV type (162). Among women who were HPV 16 or 18 DNA positive at enrollment into the clinical trials, either seropositive or seronegative, the vaccine had no efficacy against progression of infection to disease ( 159) or impact on clearance of infection of that HPV type (162). Among women who were HPV 16 or 18 DNA positive at enrollment into the clinical trials, either seropositive or seronegative, the vaccine had no efficacy against progression of infection to disease ( 159) or impact on clearance of infection of that HPV type (162). Among women who were HPV 16 or 18 DNA positive at enrollment into the clinical trials, either seropositive or seronegative, the vaccine had no efficacy against progression of infection to disease ( 159) or impact on clearance of infection of that HPV type (162). Among women who were HPV 16 or</s>